Apriem Advisors Gilead Sciences, Inc. Transaction History

Apriem Advisors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $202,624 - $227,219	-3,275 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $10,129 - $11,348	-162 Reduced 4.71%	3,275 $213,000
Q4 2018 Feb 19, 2019	SELL	$60.54 - $79.0 $48,432 - $63,200	-800 Reduced 18.88%	3,437 $215,000
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $10,692 - $11,838	150 Added 3.67%	4,237 $327,000
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $12,976 - $15,136	-200 Reduced 4.67%	4,087 $290,000
Q1 2018 May 11, 2018	BUY	$72.84 - $88.8 $58,272 - $71,040	800 Added 22.94%	4,287 $323,000
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $52,508 - $61,637	-738 Reduced 17.47%	3,487 $250,000
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $304,664 - $361,110	4,225	4,225 $342,000

1,879

1.02B

12M

8.96M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Apriem Advisors, based on Form 13F filings with the SEC.

Stay updated on Apriem Advisors with notifications on news.